Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Buchler

Showing results (461-470 of 502) with videos related to

Pageof 51
Sort By:
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 7, 2016
Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic ScreeningC Damon, M Luck, L Toullec, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trialA Molassiotis, K Jordan, M Karthaus, et al.
Frontiers in Oncology|March 18, 2024
Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib armsViktor Grünwald, Thomas Powles, Masatoshi Eto, et al.
Frontiers in Oncology|September 4, 2023
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib armsViktor Grünwald, Thomas Powles, Masatoshi Eto, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 1, 2011
Renal transplantation in patients with AA amyloidosis nephropathy: results from a French multicenter studyT Kofman, P Grimbert, F Canouï-Poitrine, et al.
European Urology Oncology|June 4, 2026
Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 StudyPhilipp Cornelius Mandel, Mike Wenzel, María Natalia Gandur Quiroga, et al.
ACS Medicinal Chemistry Letters|February 11, 2020
Synthesis and Evaluation of Bicyclic Hydroxypyridones as Inhibitors of Catechol <i>O</i>-MethyltransferaseGlen Ernst, Daniel Akuma, Vinh Au, et al.
The Lancet. Oncology|December 25, 2025
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trialKarim Fizazi, Fred Saad, Teresa Alonso-Gordoa, et al.
The New England Journal of Medicine|September 16, 2024
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder CancerThomas Powles, James W F Catto, Matthew D Galsky, et al.
Journal of the National Cancer Institute|April 25, 2012
TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort studyG Rindi, M Falconi, C Klersy, et al.
Pageof 51

Showing results (461-470 of 502) with videos related to

Sort By:
Pageof 51
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 7, 2016
Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic ScreeningC Damon, M Luck, L Toullec, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trialA Molassiotis, K Jordan, M Karthaus, et al.
Frontiers in Oncology|March 18, 2024
Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib armsViktor Grünwald, Thomas Powles, Masatoshi Eto, et al.
Frontiers in Oncology|September 4, 2023
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib armsViktor Grünwald, Thomas Powles, Masatoshi Eto, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 1, 2011
Renal transplantation in patients with AA amyloidosis nephropathy: results from a French multicenter studyT Kofman, P Grimbert, F Canouï-Poitrine, et al.
European Urology Oncology|June 4, 2026
Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 StudyPhilipp Cornelius Mandel, Mike Wenzel, María Natalia Gandur Quiroga, et al.
ACS Medicinal Chemistry Letters|February 11, 2020
Synthesis and Evaluation of Bicyclic Hydroxypyridones as Inhibitors of Catechol <i>O</i>-MethyltransferaseGlen Ernst, Daniel Akuma, Vinh Au, et al.
The Lancet. Oncology|December 25, 2025
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trialKarim Fizazi, Fred Saad, Teresa Alonso-Gordoa, et al.
The New England Journal of Medicine|September 16, 2024
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder CancerThomas Powles, James W F Catto, Matthew D Galsky, et al.
Journal of the National Cancer Institute|April 25, 2012
TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort studyG Rindi, M Falconi, C Klersy, et al.
Pageof 51